Most Read Articles
24 days ago
Regardless of dosing, nonvitamin K antagonist oral anticoagulants (NOACs) are more effective than warfarin for atrial fibrillation and safer in Asian than in non-Asian populations, a new meta-analysis shows.
9 days ago
In a Japanese population, highly myopic eyes show greater increases in axial length than nonmyopic eyes, a new retrospective longitudinal study shows. In particular, eyes with myopic choroidal neovascularization (CNV) show the greatest increases.
6 days ago
Compared with the lowest scores, the highest low-carbohydrate diet scores are associated with a 17 percent higher risk of diabetes mellitus, according to a new meta-analysis.
5 days ago
Children with sleep apnoea have significantly higher risks of developing depressive disorders than those without the sleep disorder, a new retrospective cohort study reveals.

Some mRCC patients have durable response after stopping immunotherapy

Christina Lau
5 months ago

Some patients with metastatic renal cell carcinoma (mRCC) who respond to PD-1/PD-L1 immunotherapy can have persistent clinical benefit after treatment discontinuation due to immune-related adverse events.

Among 19 patients with mRCC who responded to and subsequently discontinued PD-1/PD-L1 immunotherapy due to an immune-related adverse event, eight patients (42 percent) had durable responses and remained off any additional therapy for at least 6 months. [ASCO GU 2017, abstract 467]

“One of the eight patients had a complete response, and the remaining seven had a partial response,” reported Dr Rana R. McKay of the University of California San Diego, California, US. “These patients were on treatment for a median period of 11 months. Their median time subsequently off treatment was 20 months.”

Patients in the study (74 percent male; median age, 68 years) received PD-1/PD-L1 immunotherapy mostly as monotherapy (63 percent). The median time on immunotherapy was 5.5 months.

“Immune-related adverse events leading to immunotherapy discontinuation included arthritis, uveitis, arthropathy, hypophysitis, myositis, blepharitis, hepatitis, rash, pericarditis, and amylase and lipase elevations,” said McKay.

“It is very reassuring to see that some patients may continue to benefit from immunotherapy even after treatment discontinuation due to adverse events. These findings call into question the current standard of continuous treatment with immunotherapy,” said ASCO expert Dr Sumanta Pal of the City of Hope Cancer Center in Los Angeles, California, US.

Further studies are planned to validate the findings and investigate strategies to customize PD-1/PD-L1 immunotherapy in patients with advanced kidney cancer.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
24 days ago
Regardless of dosing, nonvitamin K antagonist oral anticoagulants (NOACs) are more effective than warfarin for atrial fibrillation and safer in Asian than in non-Asian populations, a new meta-analysis shows.
9 days ago
In a Japanese population, highly myopic eyes show greater increases in axial length than nonmyopic eyes, a new retrospective longitudinal study shows. In particular, eyes with myopic choroidal neovascularization (CNV) show the greatest increases.
6 days ago
Compared with the lowest scores, the highest low-carbohydrate diet scores are associated with a 17 percent higher risk of diabetes mellitus, according to a new meta-analysis.
5 days ago
Children with sleep apnoea have significantly higher risks of developing depressive disorders than those without the sleep disorder, a new retrospective cohort study reveals.